Allergy Month in Review: June 2025

In this month’s allergy review, several key advances indicate treatment progress. The US Food and Drug Administration (FDA) accepted the new drug application (NDA) for Anaphylm, a needle-free epinephrine film, and approved garadacimab-gxii (ANDEMBRY) for hereditary angioedema (HAE) prevention. LYR-210, a six-month nasal implant, showed strong phase 3 results for chronic rhinosinusitis (CRS).